The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The Emmy nominee also created Sherri Shepherd's sitcom and worked on 'Ellen,' 'The PJs,' 'Boardwalk Empire' and more.

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Premier research journal article provides validation for BiomX’s phage therapy platform, showcasing first-in-human Phase ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

ECMO use in cystic fibrosis with severe respiratory failure showed limited survival, highlighting the need for cautious ...

The prevalence of food allergy is significantly lower in children with cystic fibrosis than in those without the condition in ...